- Email: [email protected]
Serum IL 10 in chronic hepatitis C
Viral hepatitis: basic aspects
C05/13 ] THE EPIDEMIOLOGY OF HCV INFECTION IN ROMANIA L. Buligescu, L. Cojocaru, L. Micu Department of Internal Medicine and Hepatology,Fundeni Hospital, Bucharest. Aim of the study. To study the epidemiologieal profile o f HCV infection Romania. M a t e r i a l and method. A number o f 1055 patients diagnosed with chronic hepatitis were supervised between 1990-1999. Results. O f the total number of cases, HCV chronic hepatitis represented 55.91% (590 eases). Only 4.15% o f HCV-CH presented history of acute viral hepatitis. The main routes o f HCV transmission were transfusions 29.11%, surgery 19.86%, injections 16.16%, dental treatment 17.32%, tattoos 0.23%, hemodialysis 0.69%, peritoneal dialysis 1.38%. The degree o f histological activity and aminotransferase levels are significantly higher in patients with history o f posttransfusional acute hepatitis. Conclusions. 1. The populational prevalence o f HCV in our country is estimated at about 5%. 2. HCV was involved in the etiology o f chronic hepatitis in 55.91% o f eases. 3. The main routes o f transmission are represented by transfusions, surgery, dental treatment, injections, hemodialysis + peritoneal dialysis, tattoos and unknown in 15.24% o f eases. 5. Regarding transmission, evolution is more severe i n the ease o f history o f post-transfusional HCV acute hepatitis.
C05/14 ] CHANGES IN THE OXIDATIVE PROFILE DURING COMBINATION THERAPY (IFNa-2b+RIBAVIRIN) IN CHRONIC HEPATITIS C E Morisco, V. Verde, A. Ritieni, V. Fogliano, C. Tuccillo1, P. Iasevoli, N. Caporaso Department of Food Science,University of Naples "Federico II", Portici, Italy. 1Department of Internal Medicine,"E Magrassi" Second University of Naples, Italy. Free radicals are thought to mediate the Imthogenesis of hepatitis C v~us (HCV) infeetio~ The aim of our study was to determine ff combination treatment (interferon + n~virin = IFN + RIBA) affects sermn levels of ~ . i d e s as ~ of oxidative stress in patients with HCV-rclated chronic hepatitis. Pat~uts aad Methods: We studied 15 patients (13 M/2 F), median age 47.5 yrs (range: 32-61), affected by b i o l , - provan HCV-R.NA-positive chronic bepatitb. All received IFNa-2b (5 MU/3 times weeldy) and RIBA (1-1.2 g/die) for 6 months. A portable, floe-radical determination system (D-Reins test; Diaoron, Italy) was used to measm-e hydropercgides on serum before (To), at 3 (T3) and 6 (Te) months of treatment. Range of normal values 250-300 units (U. Cam) Rznlts: 13/15 (86.7%) patients showed an above normal value of hydroperox~s at baseline. Oxidative status has no relation to age or ALT levels. During treatment, 73.3% of showed an improved oxidative status. The mea~SD at To and T6 were respectively:. 380.7+80.5 vs 343.2+112.1 U. Cam (p<0.05). Conelmion: A large percentage of patients with chronic hepatitis C have evidence of oxidative stress. IFN+RIBA therapy modifies the oxidative profile and improves basal conditions.
I
cos/ s
I
SERUM IL 10 IN CHRONIC HEPATITIS C M.G. NeumanI, J.P. Benhamou2, N.H. Shearl, N. Borer2, P Marcellin2 1Department of Clinical Pharmacology, Sunnybrook & Women's College HSC, Toronto, Canada. 2LiverUnit, Hospital Beaujon, Paris, France. Aims: to assess serum IL 10 in chronic HCV in correlation with other parameters. We studied 48 non-cirrhotic patients that received: IFN ct 2b (3 MU 3 TIW) or IFN ¢x and ribavirin (1200 mg/day). Patients were sampled at: a- initialy; b-4 weeks; c-end (24 weeks); d-6 months after treatment. Serum IL 10 was measured by ELISA. Sustained response (SR) was define by clinic and transaminase normalization, HCV-RNA negativity at the end of treatment and maintained negativity 6 months after. Non-responders (NK) and relapse responders (RR) have none or transient changes. IL 10 is given as median (pg/mL) + SE. Mann -Whitney U test with Pearson correlation were used for statistical analysis. IFN (18 subjects) IFN+Ribavirin (30) SR/5 RR/5 NR/8 SR/10 RR/12 NR/8 a 65±5 67+7 494-6 58±4 89±6 52--~6 b 42±3 47±2 48±2 64±4 454-4 43±8 c 142±5. 594-6 65±5 430±8# 164±15. 484-6 d 1554-7. 554-5 68±6 4084-9# 694-9 52±10 *p<0.05vs. basal; #p<0.001 vs. basal. Initially, IL 10 did not differ between groups. Ribavirin enhanced the effect of IFN on ILl0 (p<0.001) having a significant correlation (r=0.025, p<0.002) with biochemistry. IL 10 increased (p<0.001) at the end of the treamaent in SRs vs. NRs orRRs IL 10 levels are higher (p<0.05) in SR combination than in monotherapy.
I
co5/ 6
I
MIP-Ip AND MCP-I AS MARKERS OF HEPATOCYTE DYSFUNCTION IN PATIENTS WITH CHRONIC HEPATITIS C J. Florholmen, M. Gangsov Kristiansenl, S. Steigen Eriksson, Z. Konopski Laboratory of Gastroenterology,Institute of Clinical Medicine, and Dep. of Pathology, University Hospital of Tromso, Tromso, Norway. ~Central Hospital of Bode, Norway. 13-chemokines play a pivotal role as chemotactic cytokines recruiting inflammatory cells into the sites of inflammation. However, the role of the 13-chemokinesin chronic hepatitis C is not well characterized. The aim of this study was to explore the role of selected 13chemokines in hepatitis C with special emphasis on their correlations to the necroinflammatory scores and biochemical activity. Serum concentrations of MIP-113, MCP-1 and RANTES were measured, using ELISA kit's, in 30 untreated patients with biopsi confirmed chronic hepatitis C. All patients were HCV RNA positive with elevated serum alanine aminotransferase (ALT) activity (range 69-356 U/I). Hepatic activity index (HAl) and necroinflarnmatory scores were assesed in all the patients. Serum from healthy subjects (n=7) represented the controls. Results: In the patient group, serum levels of MIP-113 ranged fro52 to 246 pg/ml (controls 32-40 pg/ml), MCP-1 from 62 to 965 pg/ml (controls 55-105 pg/ml), and RANTES from 7 to 89 ng/ml (controls 0-12 ng/ml). MIP-113, MCP-1, but not RANTES, correlated significantly to ALT. None of the [3-chemokines correlated significantly to the HA/and the necroinflammatory scores. In conclusion, elevated levels of MIP-II3 and MCP-1 may be markers of hepatocyte dysfunction in chronic hepatitis C.
175
C05/13 ] THE EPIDEMIOLOGY OF HCV INFECTION IN ROMANIA L. Buligescu, L. Cojocaru, L. Micu Department of Internal Medicine and Hepatology,Fundeni Hospital, Bucharest. Aim of the study. To study the epidemiologieal profile o f HCV infection Romania. M a t e r i a l and method. A number o f 1055 patients diagnosed with chronic hepatitis were supervised between 1990-1999. Results. O f the total number of cases, HCV chronic hepatitis represented 55.91% (590 eases). Only 4.15% o f HCV-CH presented history of acute viral hepatitis. The main routes o f HCV transmission were transfusions 29.11%, surgery 19.86%, injections 16.16%, dental treatment 17.32%, tattoos 0.23%, hemodialysis 0.69%, peritoneal dialysis 1.38%. The degree o f histological activity and aminotransferase levels are significantly higher in patients with history o f posttransfusional acute hepatitis. Conclusions. 1. The populational prevalence o f HCV in our country is estimated at about 5%. 2. HCV was involved in the etiology o f chronic hepatitis in 55.91% o f eases. 3. The main routes o f transmission are represented by transfusions, surgery, dental treatment, injections, hemodialysis + peritoneal dialysis, tattoos and unknown in 15.24% o f eases. 5. Regarding transmission, evolution is more severe i n the ease o f history o f post-transfusional HCV acute hepatitis.
C05/14 ] CHANGES IN THE OXIDATIVE PROFILE DURING COMBINATION THERAPY (IFNa-2b+RIBAVIRIN) IN CHRONIC HEPATITIS C E Morisco, V. Verde, A. Ritieni, V. Fogliano, C. Tuccillo1, P. Iasevoli, N. Caporaso Department of Food Science,University of Naples "Federico II", Portici, Italy. 1Department of Internal Medicine,"E Magrassi" Second University of Naples, Italy. Free radicals are thought to mediate the Imthogenesis of hepatitis C v~us (HCV) infeetio~ The aim of our study was to determine ff combination treatment (interferon + n~virin = IFN + RIBA) affects sermn levels of ~ . i d e s as ~ of oxidative stress in patients with HCV-rclated chronic hepatitis. Pat~uts aad Methods: We studied 15 patients (13 M/2 F), median age 47.5 yrs (range: 32-61), affected by b i o l , - provan HCV-R.NA-positive chronic bepatitb. All received IFNa-2b (5 MU/3 times weeldy) and RIBA (1-1.2 g/die) for 6 months. A portable, floe-radical determination system (D-Reins test; Diaoron, Italy) was used to measm-e hydropercgides on serum before (To), at 3 (T3) and 6 (Te) months of treatment. Range of normal values 250-300 units (U. Cam) Rznlts: 13/15 (86.7%) patients showed an above normal value of hydroperox~s at baseline. Oxidative status has no relation to age or ALT levels. During treatment, 73.3% of showed an improved oxidative status. The mea~SD at To and T6 were respectively:. 380.7+80.5 vs 343.2+112.1 U. Cam (p<0.05). Conelmion: A large percentage of patients with chronic hepatitis C have evidence of oxidative stress. IFN+RIBA therapy modifies the oxidative profile and improves basal conditions.
I
cos/ s
I
SERUM IL 10 IN CHRONIC HEPATITIS C M.G. NeumanI, J.P. Benhamou2, N.H. Shearl, N. Borer2, P Marcellin2 1Department of Clinical Pharmacology, Sunnybrook & Women's College HSC, Toronto, Canada. 2LiverUnit, Hospital Beaujon, Paris, France. Aims: to assess serum IL 10 in chronic HCV in correlation with other parameters. We studied 48 non-cirrhotic patients that received: IFN ct 2b (3 MU 3 TIW) or IFN ¢x and ribavirin (1200 mg/day). Patients were sampled at: a- initialy; b-4 weeks; c-end (24 weeks); d-6 months after treatment. Serum IL 10 was measured by ELISA. Sustained response (SR) was define by clinic and transaminase normalization, HCV-RNA negativity at the end of treatment and maintained negativity 6 months after. Non-responders (NK) and relapse responders (RR) have none or transient changes. IL 10 is given as median (pg/mL) + SE. Mann -Whitney U test with Pearson correlation were used for statistical analysis. IFN (18 subjects) IFN+Ribavirin (30) SR/5 RR/5 NR/8 SR/10 RR/12 NR/8 a 65±5 67+7 494-6 58±4 89±6 52--~6 b 42±3 47±2 48±2 64±4 454-4 43±8 c 142±5. 594-6 65±5 430±8# 164±15. 484-6 d 1554-7. 554-5 68±6 4084-9# 694-9 52±10 *p<0.05vs. basal; #p<0.001 vs. basal. Initially, IL 10 did not differ between groups. Ribavirin enhanced the effect of IFN on ILl0 (p<0.001) having a significant correlation (r=0.025, p<0.002) with biochemistry. IL 10 increased (p<0.001) at the end of the treamaent in SRs vs. NRs orRRs IL 10 levels are higher (p<0.05) in SR combination than in monotherapy.
I
co5/ 6
I
MIP-Ip AND MCP-I AS MARKERS OF HEPATOCYTE DYSFUNCTION IN PATIENTS WITH CHRONIC HEPATITIS C J. Florholmen, M. Gangsov Kristiansenl, S. Steigen Eriksson, Z. Konopski Laboratory of Gastroenterology,Institute of Clinical Medicine, and Dep. of Pathology, University Hospital of Tromso, Tromso, Norway. ~Central Hospital of Bode, Norway. 13-chemokines play a pivotal role as chemotactic cytokines recruiting inflammatory cells into the sites of inflammation. However, the role of the 13-chemokinesin chronic hepatitis C is not well characterized. The aim of this study was to explore the role of selected 13chemokines in hepatitis C with special emphasis on their correlations to the necroinflammatory scores and biochemical activity. Serum concentrations of MIP-113, MCP-1 and RANTES were measured, using ELISA kit's, in 30 untreated patients with biopsi confirmed chronic hepatitis C. All patients were HCV RNA positive with elevated serum alanine aminotransferase (ALT) activity (range 69-356 U/I). Hepatic activity index (HAl) and necroinflarnmatory scores were assesed in all the patients. Serum from healthy subjects (n=7) represented the controls. Results: In the patient group, serum levels of MIP-113 ranged fro52 to 246 pg/ml (controls 32-40 pg/ml), MCP-1 from 62 to 965 pg/ml (controls 55-105 pg/ml), and RANTES from 7 to 89 ng/ml (controls 0-12 ng/ml). MIP-113, MCP-1, but not RANTES, correlated significantly to ALT. None of the [3-chemokines correlated significantly to the HA/and the necroinflammatory scores. In conclusion, elevated levels of MIP-II3 and MCP-1 may be markers of hepatocyte dysfunction in chronic hepatitis C.
175